Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada
- 10 March 2011
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 19 (2) , 221-230
- https://doi.org/10.1177/1741826711400545
Abstract
Background: The prevalence of persistent lipid abnormalities in patients receiving statins in primary and secondary care is needed to formulate recommendations for future treatment. Studies associating cardiovascular risk factors with lipid target goal achievement are lacking.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisPublished by Elsevier ,2008
- New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular diseaseCurrent Cardiology Reports, 2007
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)European Heart Journal, 2007
- Economic burden of cardiovascular diseases in the enlarged European UnionEuropean Heart Journal, 2006
- Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight LossCirculation, 2006
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Global Prevalence of DiabetesDiabetes Care, 2004
- High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery diseaseAmerican Heart Journal, 2002
- Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its ApolipoproteinsCirculation, 2001